Infliximab Biosimilar Market
完整報告名稱與涵蓋範圍
Infliximab Biosimilar Market Size, Share & Trends Analysis Report By Brand, Applications (Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others), Distribution Channel, Region And Segment Forecasts, 2025-2034
報告摘要
The global Infliximab Biosimilar Market is set to witness pronounced expansion over the coming years.
At its core, Infliximab Biosimilar pertains to landscape are mountingly turning to these solutions to meet contemporary demands.
Market momentum is bolstered by mounting call for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Infliximab Biosimilar Market Snapshot
Chapter 4. Global Infliximab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Infliximab Biosimilar Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Infliximab Biosimilar Market Industry Trends
Chapter 5. Infliximab Biosimilar Market Segmentation 1: By Brand, Estimates & Trend Analysis
5.1. Market Share by Brand, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Brand:
5.2.1. Avsola (infliximab-axxq)
5.2.2. Flixabi (SB2)
5.2.3. Inflectra (infliximab-dyyb)
5.2.4. Ixifi (infliximab-qbtx)
5.2.5. Remicade
5.2.6. Zessly
5.2.7. Infimab (BOW015)
5.2.8. NI-071
5.2.9. Infliximab BS
5.2.10. CMAB008
5.2.11. Others (Products approved in developing countries & pipeline products)
Chapter 6. Infliximab Biosimilar Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Crohn's Disease
6.2.2. Psoriatic Arthritis
6.2.3. Rheumatoid Arthritis
6.2.4. Ulcerative Colitis
6.2.5. Ankylosing Spondylitis
6.2.6. Plaque Psoriasis and others
Chapter 7. Infliximab Biosimilar Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
7.2.1. Hospital Pharmacy
7.2.2. Online Pharmacy
7.2.3. Retail Pharmacy
7.2.4. Other Direct Distribution Channels
Chapter 8. Infliximab Biosimilar Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Infliximab Biosimilar Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.2.3. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.3. Europe
8.3.1. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.3.3. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.4.3. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.5. Latin America
8.5.1. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.5.3. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.6.3. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Amgen
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Samsung Bioepis
9.2.3. Celltrion
9.2.4. Pfizer
9.2.5. Johnson & Johnson
9.2.6. Sandoz (Novartis division)
9.2.7. Epirus Biopharmaceuticals
9.2.8. Nichi-Iko Pharmaceutical
9.2.9. Mabpharm
9.2.10. Biogen
9.2.11. Merck (MSD)
9.2.12. Ranbaxy Laboratories (now Sun Pharma)
9.2.13. Sorrento Therapeutics (partner)
9.2.14. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們